Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir. 1998

C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001727 Bisexuality The sexual attraction or relationship between members of both the same and the opposite SEX.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015528 HIV Seroprevalence Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV SEROPOSITIVITY). Seroprevalence, HIV
D016049 Didanosine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. 2',3'-Dideoxyinosine,Dideoxyinosine,ddI (Antiviral),NSC-612049,Videx,2',3' Dideoxyinosine,NSC 612049,NSC612049
D017088 AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. HIV-Related Opportunistic Infections,Opportunistic Infections, AIDS-Related,Opportunistic Infections, HIV-Related,AIDS Related Opportunistic Infections,AIDS-Related Opportunistic Infection,HIV Related Opportunistic Infections,HIV-Related Opportunistic Infection,Infection, HIV-Related Opportunistic,Infections, HIV-Related Opportunistic,Opportunistic Infection, AIDS-Related,Opportunistic Infection, HIV-Related,Opportunistic Infections, AIDS Related,Opportunistic Infections, HIV Related

Related Publications

C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
November 1997, AIDS (London, England),
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
June 1997, Uirusu,
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
December 2002, Uirusu,
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
July 1998, The Journal of general virology,
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
September 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
January 1998, AIDS (London, England),
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
January 1999, Advances in cancer research,
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
December 2003, Journal of medical virology,
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
April 2004, Expert review of anti-infective therapy,
C Martinelli, and M Zazzi, and S Ambu, and D Bartolozzi, and P Corsi, and F Leoncini
January 1997, IARC monographs on the evaluation of carcinogenic risks to humans,
Copied contents to your clipboard!